Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Borg

Showing results (71-80 of 224) with videos related to

Pageof 23
Sort By:
Frontiers in Oncology|March 28, 2022
Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective PatientsEmeline Orillard, Julie Henriques, Dewi Vernerey, et al.
Clinical Medicine Insights. Oncology|September 19, 2015
Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive DiseaseCélia Turco, Marine Jary, Stefano Kim, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 17, 2024
Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trialThibault Mazard, Caroline Mollevi, Evelyne M Loyer, et al.
British Journal of Clinical Pharmacology|December 10, 2023
Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patientsSarah Lobet, Morgane Caulet, Gilles Paintaud, et al.
Experimental Hematology|February 21, 2007
Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytesEmilie Brillard, Jean-René Pallandre, David Chalmers, et al.
Gut|October 20, 2009
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancerBoris Guiu, Jean Michel Petit, Franck Bonnetain, et al.
The Journal of Molecular Diagnostics : JMD|July 12, 2011
A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancersSandrine Magnin, Erika Viel, Alice Baraquin, et al.
Clinical Colorectal Cancer|November 28, 2021
Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II StudyAurelie Bertaut, Yann Touchefeu, Julie Blanc, et al.
Breast Cancer Research : BCR|October 27, 2012
High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patientsNicolas Pernodet, François Hermetet, Pascale Adami, et al.
Cancer Research|July 19, 2005
BCR/ABL promotes dendritic cell-mediated natural killer cell activationMagali Terme, Christophe Borg, François Guilhot, et al.
Pageof 23

Showing results (71-80 of 224) with videos related to

Sort By:
Pageof 23
Frontiers in Oncology|March 28, 2022
Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective PatientsEmeline Orillard, Julie Henriques, Dewi Vernerey, et al.
Clinical Medicine Insights. Oncology|September 19, 2015
Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive DiseaseCélia Turco, Marine Jary, Stefano Kim, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 17, 2024
Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trialThibault Mazard, Caroline Mollevi, Evelyne M Loyer, et al.
British Journal of Clinical Pharmacology|December 10, 2023
Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patientsSarah Lobet, Morgane Caulet, Gilles Paintaud, et al.
Experimental Hematology|February 21, 2007
Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytesEmilie Brillard, Jean-René Pallandre, David Chalmers, et al.
Gut|October 20, 2009
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancerBoris Guiu, Jean Michel Petit, Franck Bonnetain, et al.
The Journal of Molecular Diagnostics : JMD|July 12, 2011
A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancersSandrine Magnin, Erika Viel, Alice Baraquin, et al.
Clinical Colorectal Cancer|November 28, 2021
Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II StudyAurelie Bertaut, Yann Touchefeu, Julie Blanc, et al.
Breast Cancer Research : BCR|October 27, 2012
High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patientsNicolas Pernodet, François Hermetet, Pascale Adami, et al.
Cancer Research|July 19, 2005
BCR/ABL promotes dendritic cell-mediated natural killer cell activationMagali Terme, Christophe Borg, François Guilhot, et al.
Pageof 23